NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

The 2018 SNO presentation estimated that 36 months past surgery (33 months past randomization), 87 patients were still at risk. I am estimating that at least 80 such patients still existed 3 months later (at 36 months past randomization). The November 2018 SNO estimate was perhaps made a few months earlier than November but at that time probably all the trial's living patients were at least 30 months on trial and that estimate was therefore pretty accurate.

So of at least 80 post 36 months survivors, I have estimated a total of about 58 post 36 months survivors in the Treatment group. Therefore at least about 22 would be found in the group of 99 intend to cross over group.

Why don't you use the official data from the NYAS presentation, Meirluc?

Slide 29.

DCVax-l patients at risk 36 months from randomization = 45 patients. (30 MGMT methylated DCVax-L - 14 MGMT unmethylated DCVax-L and 1 MGMT unknown DCVax-L patient)

IMO,
58 DCVax-L patients at risk 32.9 months from randomization. (36 months from surgery)
30 or 31 placebo patients at risk 32.9 months from randomization.(36 months from surgery)
We have a lot of data, Meirluc. Try to make the overall survival Kaplan Meier curves of the MGMT methylated placebo patients and the MGMT unmethylated placebo patients.(And eventually the OS KM curve of the MGMT unknown placebo patients) Interesting curves IMO.